Cardiotoxic mechanisms of cancer immunotherapy - A systematic review

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:323

Review

Lobenwein, Daniela^1,2  Kocher, Florian³  Dobner, Stephan⁴  Gollmann-Tepekoylu, Can¹  Holfeld, Johannes¹ 

[1] Innsbruck Med Univ, Univ Clin Cardiac Surg, Anichstr 35, A-6020 Innsbruck, Austria

[2] Innsbruck Med Univ, Div Clin & Funct Anat, Innsbruck, Austria

[3] Innsbruck Med Univ, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria

[4] Inselspital Bern, Dept Cardiol, Bern, Switzerland

关键词: Cancer immunotherapy;    Cardiovascular toxicity;    Cardiooncology;    Translational medicine;   

DOI  :  10.1016/j.ijcard.2020.08.033

来源: Elsevier

【 摘 要 】

Cancer immunotherapy is a success story of translational medicine that has led to improved survival in patients with different difficult-to-treat types of cancer, such as metastasized melanoma, non-small cell lung cancer or renal cell carcinoma. These novel therapeutic agents exert their antitumor effects by activating the patients' immune system against cancer cells. Immunotherapy can be divided into active agents, such as anti-tumour vaccines or adoptive T-cell transfer, and passive immunotherapies like monoclonal antibodies, checkpoint inhibitors, cytokine therapy, bispecific T-cell engagers. After initial experimental use, broad clinical application revealed a number of important cardiovascular side effects of immunotherapeutics, which limit treatment options and decrease patients' prognosis and quality of life. With the rising rate of new immunotherapeutics at a hand, the number of patients receiving cancer immunotherapy will constantly increase, resulting in improved long-term survival rates. This review aims to summarize available cancer immunotherapies, their mechanism of action, currently known cardiovascular toxicities and their treatment. Further optimization of patient care will depend on the combined efforts by oncologists, cardiologists and cardiac surgeons to identify patients at risk and the implementation of interdisciplinary screening and treatment strategies. It is therefore crucial to familiarize heart specialists with novel cancer therapeutics and their potential adverse effects. (C) 2020 The Authors. Published by Elsevier B.V.

【 授权许可】

Free